[Federal Register Volume 67, Number 46 (Friday, March 8, 2002)]
[Notices]
[Pages 10732-10733]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-5568]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Exclusive License: Growing Ehrlichia Species 
in a Continuous Cell Line

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the Centers for Disease Control and Prevention 
(CDC), Technology Transfer Office, Department of Health and Human 
Services (HHS), is contemplating the grant of a worldwide, limited 
field of use, exclusive license to practice the inventions embodied in 
the patent and patent applications referred to below to Intervet Inc. 
(Intervet) having a place of business in Millsboro, Delaware. The 
patent rights in these inventions have been assigned to the government 
of the United States of America. The patent and patent applications to 
be licensed are:

[[Page 10733]]

    Title: Growing Ehrlichia Species in a Continuous Cell Line U.S. 
Patent Application Serial No. 07/518,182.
    Filing Date: 05/03/90.
    Domestic Status: Patent No.: 5,192,679.
    Issue Date: 03/09/93.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
    Ehrlichiosis is a non-communicable, rarely fatal, rickettsial 
disease found in the United States. It is clinically similar to Rocky 
Mountain Spotted Fever but lacks the distinctive rash and is related to 
Sennetsu Fever, found only in Japan. In the United States ehrlichiosis 
is caused primarily by E. Chaffeensis. The development of diagnostics 
and vaccines for these diseases has been hampered by a lack of 
continuous cell lines to produce large quantities of Ehrlichia 
antigens. In this invention, a method of growing pathogenic Ehrlichia 
species in the continuous monocyte-macrophage cell line DH82 has been 
developed.

ADDRESSES: Requests for a copy of these patent applications, inquiries, 
comments, and other materials relating to the contemplated license 
should be directed to Andrew Watkins, Director, Technology Transfer 
Office, Centers for Disease Control and Prevention (CDC), 4770 Buford 
Highway, Mailstop K-79, Atlanta, GA 30341, telephone: (770) 488-8610; 
facsimile: (770) 488-8615. Applications for a license filed in response 
to this notice will be treated as objections to the grant of the 
contemplated license. Only written comments and/or applications for a 
license which are received by CDC within sixty days of this notice will 
be considered. Comments and objections submitted in response to this 
notice will not be made available for public inspection, and, to the 
extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552. A signed Confidential Disclosure 
Agreement will be required to receive a copy of any pending patent 
application.

    Dated: March 4, 2002.
Joseph R. Carter,
Associate Director for Management and Operations, Centers for Disease 
Control and Prevention.
[FR Doc. 02-5568 Filed 3-7-02; 8:45 am]
BILLING CODE 4163-18-U